News | Annuloplasty Rings | July 20, 2016

TITAN II Data Confirm Safety, Efficacy of Carillon Mitral Contour System

Results confirm functional improvement, reduction in heart failure hospitalizations seen in previous trials

TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR

July 20, 2016 — New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment of functional (secondary) mitral regurgitation (FMR).

The Carillon System, a transcatheter mitral annuloplasty device, can be deployed rapidly and safely, utilizing standard interventional techniques. The device is placed using a non-surgical, minimally invasive (catheter-based) technique in a vein on the outside of the heart that is adjacent to the mitral valve. This simple procedure is designed to reshape the mitral valve annulus, reduce valve leakage and thus reduce mitral regurgitation.

According to data published in Open Heart, an official journal of the British Cardiovascular Society, on July 8, treatment with the Carillon device significantly reduced annular dimensions and improved mitral regurgitation, heart failure symptoms and functional capacity in patients with FMR. The results also show a decrease in heart failure hospitalizations in the one-year follow-up period when compared to the year prior to implantation. These improvements were similar to those seen in prior studies.

The TITAN II trial was a prospective, single-arm, multi-center study, undertaken at five centers in Germany, Poland and France. Two prior multi-center studies (AMADEUS and TITAN) using the Carillon system also provided compelling evidence of safety and efficacy. In total, more than 100 FMR patients have now been evaluated in multi-center studies featuring the Carillon device.

“This is the second multi-center study featuring the Carillon device in which I have participated and I’ve become more impressed with how the therapy improves symptoms and quality of life in these patients by addressing annular dilatation, a root cause of FMR,” said lead investigator Janusz Lipiecki, M.D., Ph.D., from Pôle Santé République, Clermont-Ferrand, France. “The minimally invasive nature and simplicity of the Carillon system make it an extremely important therapy for this otherwise under-addressed, severely ill heart failure population. “

The Carillon system is now being evaluated in the landmark REDUCE FMR Trial, the first randomized, blinded evaluation of a therapy for FMR. The trial will enroll 120 patients at 25 centers in Europe, Australia and New Zealand, with the goal of establishing the Carillon system as the gold standard therapy for FMR.

The Carillon system has received CE Mark approval and is commercially available in the European Union.

For more information: www.cardiacdimensions.com

Related Content

Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings| October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings| February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings| September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init